provide evidence that i.m. buspirone blocks D 3 R and D 2 R, whereas oral buspirone is more selective towards D 3 R blockade in vivo, consistent with extensive first pass metabolism and supporting the hypothesis that its metabolites (5-and 6′-hydroxybuspirone) merit evaluation for treating SUDs. They also indicate that for oral buspirone to achieve greater than 80% sustained D 3 R occupancy, as might be needed to treat addiction, higher doses (at least three-fold) than those used to treat anxiety (maximal 60 mg) will be required. Nonetheless, based on previous clinical studies, these doses would be safe and well tolerated.
Introduction
There is an urgent need for better addiction treatments. The economic costs as a result of substance use disorders (SUD) (e.g. health care, lost productivity, criminal justice) are estimated at more than half a trillion dollars annually in the United States (Volkow and Li, 2005) . Despite a devastating impact on public health, there are very few medications for the treatment of SUD, and these are restricted to alcohol, nicotine and opiate use disorders.
Insights into the neurobiological bases of addiction have highlighted the need for medications, which are able to either, reverse or compensate for addiction related changes in brain function (Kalivas and Volkow, 2011) . Among these changes, mitigating the disruption of dopamine modulated striato-cortical circuits produced by chronic exposure to addictive drugs is an attractive target for medication development. This circuitry plays a critical role in the ability to control strong urges, and its disruption is implicated in the inability of an addicted person to stop using drugs, resulting in compulsive administration despite awareness of its potentially catastrophic consequences.
There are now converging lines of evidence that signalling mediated by the dopamine D 3 receptor (D 3 R) is critical to the addictive process. For example, an upregulation of D 3 R has been reported in post-mortem brains of individuals addicted to cocaine (Staley and Mash, 1996) . Moreover, a recent positron emission tomography (PET) imaging study using the D 3 -preferring radioligand [ highly concentrated localization of D 3 R in regions of the brain reward circuitry (midbrain, ventral striatum, pallidum) (Sokoloff et al., 1990; Murray et al., 1994) has generated interest in investigating the potential of D 3 R as a molecular target for addiction treatments (Heidbreder and Newman, 2010) . Indeed, in pre-clinical models D 3 R antagonists interfere with both self-administration (especially when the work demand for the reinforcer is increased) and relapse (reinstatement) against multiple drugs of abuse (Le Foll et al., 2005; Heidbreder and Newman, 2010) .
While multiple D 3 R antagonists are available for pre-clinical studies (Heidbreder et al., 2005; Newman et al., 2012) , only one report of a compound (GSK 598809) with the appropriate safety profile for use in humans has been published (Mugnaini et al., 2013) . Consistent with the pre-clinical profile of D 3 R antagonists, GSK 598809 produced a transient reduction in craving for cigarettes in smokers after overnight abstinence. This effect was produced when occupancy of D 3 R assessed with PET and [ 11 C]PHNO was estimated to be 72-89%. Further development of this compound was, however, halted by the sponsor (Newman et al., 2012) .
Buspirone (Buspar ® ), an anxiolytic initially described as a selective 5-HT 1A partial agonist Loane and Politis, 2012) , has been shown by in vitro studies to also bind to D 3 receptors (D 3 R, Ki = 98 nM) and D 4 receptors (D 4 R, Ki = 29.2 nM) with affinities similar to those reported at 5-HT 1A receptors (Ki = 4-78 nM), and behaves as an antagonist at these dopamine receptors . Buspirone also binds to D 2 receptors (D 2 R, Ki = 484 nM), albeit with a much lower affinity compared to 5-HT 1A , D 3 R, and D 4 R. Consistent with this neurochemical profile, buspirone (0.1-0.32 mg/kg, i.m.) inhibited self-administration of cocaine at all unit doses in rhesus monkeys Mello et al., 2013) and interfered with relapse to stimulant administration triggered by stress, cues, and drug priming in rodents (Newman et al., 2012) . In this preliminary study, we tested the hypothesis that buspirone at doses within the range used clinically induces significant occupation of D 3 R in the living nonhuman primate brain, which would support its use in clinical trials for the treatment of addiction and provide information regarding dosing. To test this hypothesis, we used PET in conjunction with the D 3 R-preferring radiotracer, [ 11 C]PHNO (K d = 0.07 nM for D 3 R; 148-fold selectivity for D 3 R over D 2 R) (Wilson et al., 2005b; Parker et al., 2006) , to measure D 3 R occupancy by buspirone and compared it with the occupancy derived with [ 11 C]raclopride, which binds to D 2 R (1.5-1.6 nM) and D 3 R (1.2-2.1 nM) almost equally (Malmberg et al., 1994; Seeman, 2001) . In addition, the distinct localization of D 2 R and D 3 R in the basal ganglia and the midbrain provides another means of distinguishing the binding of ]PHNO in dorsal striatum, which has a much higher expression of D 2 R relative to D 3 R, is likely to reflect binding to both receptors whereas binding in the midbrain and pallidum is likely to predominantly reflect occupation of D 3 R (Tziortzi et al., 2011) . We also measured in vivo binding of buspirone on D 1 receptors (D 1 R) using a D 1 R selective radioligand, [
11 C]NNC-112 (Halldin et al., 1998) . D 1 R concentration is high in mesolimbic areas and is implicated in cocaine reward and addiction (Campbell et al., 1999; Edwards et al., 2007; Graham et al., 2007 would result in a slower rate of dissociation. Our initial experimental design aimed to assess the effects of parenteral buspirone in blocking D 3 R; but after observing significant blockade of D 2 R (assessed with [ 11 C]raclopride) we decided to also measure the effects of orally administered buspirone. This was relevant since oral buspirone is subject to extensive first pass metabolism (Gammans et al., 1986; Jajoo et al., 1989) and its metabolites bind with higher affinity for D 3 R relative to D 2 R . Indeed the affinity of 6′-hydroxybuspirone, (which reaches plasma concentrations ∼40-fold higher than buspirone after oral administration of the parent drug (Dockens et al., 2006) , for D 3 R (795 nM) is higher relative than that of D 2 R (5390 nM) . While plasma concentrations of 5-hydroxybuspirone, approximate those of the parent compound following oral administration (Gammans et al., 1986) ; it could also contribute based on its higher affinity for D 3 R (261 nM) relative to D 2 R (4010 nM) .
Materials and method

Ethics statement
All baboons (Papio Anubis) were maintained at Brookhaven National Laboratory (BNL) Animal Facility in accordance with the United States Department of Agriculture (USDA) and New York State Department of Health animal welfare regulations. BNL is fully accredited by the Association for Assessment and Accreditation of Laboratory Animal Care International, and maintains an assurance with the Office of Laboratory Animal Welfare (OLAW). All work conducted on the animals used in this study was performed under protocols approved by the BNL Institutional Animal Care and Use Committee (IACUC). Briefly, the baboons used in this study were singly housed in stainless steel caging that provided enrichment and interaction for each animal. The baboon's daily diet consisted of a commercial primate diet (Fiber Plus Primate, Purina Mills, USA) along with supplemental fresh fruits and vegetables and other food enrichment. Fresh drinking water was provided ad libitum via an automatic watering system. All husbandries, environmental enrichment, veterinary, and other such procedures were performed in compliance with the Guide for the Care and Use of Laboratory Animals and the Animal Welfare Act. Animal health was monitored daily by certified animal care staff and veterinary personnel, available 24/7. Baboons showing signs of disease or distress that could not be alleviated using standard analgesics and/or chemotherapy were humanely euthanized using an overdose of barbiturates according to the guidelines of the American Veterinary Medical Association. It is noteworthy, however, that none of the animals became ill and/or met the criteria for the IACUC approved end-point policy during this study period, therefore, none were euthanized.
Subjects
Seven female baboons (13.5∼21 kg) were studied in 51 PET scans (90 min scan) in which 3 radiotracers were administered with or without buspirone pre-treatment. the time interval between scans was at least 3 wk to minimize 'mass carry-over effect' between scans in the same subject (Girgis et al., 2011; Gallezot et al., 2012; Searle et al., 2013) . In order to minimize ketamine-induced endogenous dopamine receptor occupancy (Smith et al., 1998) , ketamine was administrated at least 3.5 h before
Drugs
Buspirone hydrochloride (purity > 99.0%) was purchased from Sigma Aldrich and was used without further purification. Buspirone was administered orally, intramuscularly or intravenously. Estimated as free-base, buspirone was weighed and dissolved into 2.0 ml of sterile saline. This solution was then passed through a sterilizing 0.2 mm HT Tuffryn ® Membrane filter (25 mm housing, Pall Co., USA) into a sterile, pyrogen-free vial. Oral doses were dissolved in saline (10 ml). 6′-hydroxybuspirone (hydrogen chloride salt form) was obtained from Dr Rik Kline (Chemistry and Pharmaceutics Branch, National
Institute on Drug Abuse). 6′-hydroxybuspirone (1 mg/ kg) was dissolved in saline (3 ml) and passed through a filter (25 mm housing, Pall Co., USA) into a sterile vial.
Radiotracer synthesis After purification of the radiotracers by high performance chromatography, the HPLC solvent was evaporated under the reduced pressure. All radiotracers were formulated using saline (8 ml) and filtered through a sterile filter (Acrodisc ® 13 mm with 0.2 μm HT Tuffryn ® Membrane, Pall Co., USA) to give a sterile, pyrogen-free injection solution. The radiochemical purity was >99%.
PET imaging
Dynamic PET scans were performed on a Siemens HR+ high-resolution scanner (4.5 × 4.5 × 4.8 mm at the centre of the field of view, 63 planes) in 3-dimensional acquisition mode. A transmission scan was obtained with a 68
Ge rotating rod source prior to radiotracer injection to correct for attenuation of the emission scans. The baboons were anesthetized with a dose of ketamine (10 mg/kg); intubated and ventilated with a mixture of isoflurane (1-4%, Forane; Baxter Healthcare Corp.), nitrous oxide (1500 ml/min), and oxygen (800 ml/min); and then catheterized for radiotracer injection as previously described ]NNC-112. The oral doses of buspirone were administered through a nasogastric tube, which was flushed with saline (10 ml) as described elsewhere . Additionally, we did one study to assess the effects of 6′-hydroxybuspirone (1 mg/kg), which was administered i.m. 3 h prior to [ 11 C]PHNO injection (injected mass, 0.9 μg).
Image analysis
PMOD (PMOD Technologies Ltd, Switzerland) was used for image analysis. All reconstructed image data were converted to the ANALYZE format and co-registered with H 2 15 O template images as described previously (Kim et al., 2007) . Regions of interest (ROIs) were placed over the caudate (CD), putamen (PU), globus pallidum (GP), midbrain [centre in substantia nigra, (SN)] and the cerebellum (CB) in the summed baseline images and adjusted manually from an MR template (Black et al., 2001) . These ROIs were projected onto the co-registered dynamic images to obtain time-activity curves (TACs). Averaged TACs for the standard uptake values (SUV) of each radiotracer were computed to assess differences between baseline and buspirone. The simplified reference tissue model (SRTM2) (Lammertsma and Hume, 1996; Shotbolt et al., 2012) was applied into each ROI to obtain the non-displaceable binding potential (BP nd ) using the cerebellum as a reference tissue for all three radiotracers. Differences in BP nd between control and buspirone pretreatment scans were used to estimate drug occupancies as follows: 
Results
Effects of buspirone (IM and PO) on radiotracer binding
The TACs of [ Parenteral buspirone significantly reduced TACs for [ 11 C]PHNO in putamen and globus pallidum for the 0.19 mg/kg (t = 1.8, p = 0.05 and t = 3, p = 0.005, respectively) and the 0.5 mg/kg doses (t = 2.6, p = 0.01 and t = 4.45, p = 0.0002), while the effects in cerebellum were not significant (t < 1.2, p > 0.13). Similarly, oral buspirone (3 mg/kg) significantly decreased TACs for [ 11 C]PHNO in putamen (t = 1.8, p = 0.05) and globus pallidum (t = 3, p = 0.005) and showed a trend in cerebellum (t = 1.6, p = 0.06) (Fig. 2) . The trend of an effect in cerebellum is consistent with the low density of D 3 R in cerebellum detected by (F = 36, p = 0.003). Post-hoc t-tests showed significant reductions in caudate after 0.25 h (t = 9.5, p = 0.01) and 2.25 h (t = 5, p = 0.04) and in putamen after 0.25 h (t = 8.9, p = 0.01) and a trend at 2.25 h (t = 3.2, p = 0.08). For the 0.5 mg/kg IM dose (n = 3, 4 repeated measures) there was a significant main effect in caudate (F = 11.5, p = 0.007) and putamen (F = 10.6, p = 0.008). Post hoc t tests showed significant reductions in caudate after 2 h (t = 4.5, p = 0.04), 4 h (t = 6.2, p = 0.03) and 6 h (t = 5.6, p = 0.03) and in putamen after 2 h (t = 4.9, p = 0.04), 4 h (t = 11, p = 0.008) and a trend at 6 h (t = 3.5, p = 0.07). For oral buspirone (n = 4, 4 repeated measures) the main effect was significant in caudate (F = 7.6, p = 0.008) and putamen (F = 5.8, p = 0.02) and the post-hoc t tests showed that decreases were significant only at 5 h in caudate (t = 3.2, p = 0.05) and putamen (t = 4.5, p = 0.02).
Statistical analysis (paired t tests, n = 2) to assess the effects of buspirone on BP ND for [ 11 C]PHNO (Supplementary Table 2) showed that for i.m. only the comparisons between baseline and the 0.5 mg/kg i.m. dose in midbrain (where the substantia nigra is located) was significant (t = 12, p = 0.05) whereas for oral buspirone the decreases were significant in putamen (t = 37, p = 0.02) and midbrain (t = 59, p = 0.01) and showed a trend in GP (t = 9.2, p = 0.07). (Fig. 4) . For the higher i.m. buspirone dose (0.5 mg/kg) the occupancy in putamen at 2 h was 54 ± 15%, at 4 h it was 37 ± 8% and by 6 h it had decreased to 26 ± 13% (Fig. 4) . Results in caudate are similar to those in putamen (Fig. 4) .
Buspirone (0.19 mg/kg, i.m.) reduced [ 11 C]PHNO BP nd at 0.25 h after pre-treatment, corresponding to an occupancy of 63% in PU and 61% in globus pallidum (GP) and by 2 h the occupancy had decreased to 20 ± 6% (n = 2) (Fig. 5) . For the higher buspirone dose (0.5 mg/kg i.m. n = 2) the occupancy at 2.25 h was 42 ± 15%. Results in caudate are similar to those in putamen (Fig. 5 and Supplementary Table 2 ).
Receptor occupancies with oral buspirone
The low dose of oral buspirone (1 mg/kg, n = 1, data not shown) produced minimal decreases in [ 11 C]PHNO BP ND , with estimated occupancies at 1 h postadministration in caudate of 14%, in PU of 9% and in GP of 20%. The higher dose (3 mg/kg, n = 3) resulted in significant blockade of [ 11 C]PHNO BP nd when measured 3 h after its administration corresponding to occupancies of 44 ± 19% in PU, 55 ± 12% in GP and 74 ± 13% in midbrain (location of SN) (Fig. 5) .
The higher dose of oral buspirone (3 mg/kg, n = 4) elicited minimal blockade of [ 11 C]raclopride's specific binding 1 h post-administration (caudate:29 ± 18%; putamen: 37 ± 32%) that had mostly cleared after 2 h post-administration (caudate 10 ± 6%; putamen 10 ± 10%) (Fig. 4) . Since the high dose had minimal effects on [ 11 C]raclopride's BP nd , the effects of the low buspirone dose (1 mg/kg) were not examined. Comparisons of D 2 R occupancy between i.m. and oral busprione showed it was significantly higher after i.m. (2 h measures) than after oral buspirone (3 h measures; n = 3) in caudate (55 ± 12% vs. 10.5 ± 8%; t = 4.2, p = 0.05) and in putamen (64 ± 16% vs. 11 ± 12%; t = 4.1, p = 0.05). 
Discussion
Here, we document that buspirone (oral and parenteral) significantly blocks D 3 R in the living baboon brain at doses that are clinically relevant. We also demonstrate higher selectivity of oral buspirone for D 3 R relative to D 2 R when compared to i.m. buspirone. Consistent with the relatively low affinity of buspirone for D 1 R in vitro , we found no blockade of D 1 R by buspirone.
Specifically, our preliminary data show that parenteral buspirone at doses that interfere with cocaine reward in rodents and in non-human primates Mello et al., 2013) demonstrating that buspirone exhibits high affinity for recombinant D 3 R . The fast occupancy of D 3 R by oral and i.m. buspirone is consistent with pharmacokinetics studies that reported peak plasma buspirone concentrations after oral administration within 1 h in humans (Gammans et al., 1986 ) and non-human primates (Marathe et al., 1999) . We were unable to find a pharmacokinetic analysis for i.m. buspirone, but since pharmacologically relevant concentrations have been reported within 15 min of i.m. buspirone we predict that peak concentrations after i.m. buspirone will be reached sooner than after oral buspirone. Future studies evaluating occupancies at different time-points are necessary to estimate the pharmacokinetics for the occupancy of D 3 R by buspirone in brain. We also showed that i.m. buspirone produces a significant blockade of [ 11 C]raclopride binding. In contrast, oral buspirone had a minimal effect in [ 11 C]raclopride binding, showing a higher selectivity of D 3 R blockade over D 2 R blockade than i.m. administration. Indeed, despite the small sample size (n = 3) the difference on D 2 R occupancies in dorsal striatum between oral and i.m. was significant. Similarly, despite the small sample sizes (n = 2) we showed that oral buspirone significantly reduced [
11 C]PHNO binding in midbrain and showed a lower trend in pallidum (areas rich in D 3 R). Our ability to show significant differences even with the small sample sizes indicates that these are large effects. The higher selectivity of oral buspirone for D 3 R relative to i.m. buspirone is consistent with the extensive first pass metabolism of orally administrated buspirone, which limits bioavailability of the parent compound (only 4% in humans) (Mayol et al., 1985) , and results in two active metabolites (5-and 6′-hydroxybuspirone) that possess a higher affinity for D 3 R (5-hydroxybuspirone, Ki = 261 nM; 6′-hydroxybuspirone, Ki = 795 nM) relative to D 2 R (5-hydroxybuspirone, Ki = 4010 nM; 6′-hydroxybuspirone, Ki = 5390 nM) in vitro . Prior PET studies had reported differences between the parent compound and its metabolite for clomipramine and desclomipramine (Takano et al., 2011) and for quetiapine and norquetiapine (Nyberg et al., 2013) .
It is important to note that buspirone and the 5′-and 6′-hydroxy metabolites also possess high affinity and antagonistic efficacy for D 4 R in vitro (5-hydroxybuspirone, Ki = 107 nM; 6′-hydroxybuspirone, Ki = 40 nM) . Since there is in vivo evidence that D 4 R antagonists are effective (Feldpausch et al., 1998; Yan et al., 2012) in animal models of SUD, this highlights a potential role of D 4 R antagonism in the anti-addictive properties of buspirone. Moreover, given that the affinity of 6′-hydroxybuspirone, a metabolite with a total plasma exposure ∼40-fold higher than buspirone following oral administration (Dockens et al., 2006) approximates that of the parent drug at D 4 R , it is likely that D 4 R occupancy would be similar or higher than at D 3 R.
Pharmacokinetic differences in drug delivery into the brain are also likely to contribute to higher D 2 R binding for i.m. than oral administration since IM buspirone would result in higher and faster brain levels of the parent compound than with oral buspirone, which is extensively metabolized. However, for D 3 R occupancy, the higher affinity of buspirone's metabolites for D 3 R relative to those of the parent compound offsets the slower brain delivery of buspirone with oral administration.
Significant inhibition of [ 11 C]raclopride binding in the dorsal striatum following i.m. buspirone indicates that buspirone occupies D 2 R. Buspirone has been known to possess D 2 R antagonist properties (Riblet et al., 1982; Dhavalshankh et al., 2007; Bergman et al., 2013) . This could be of potential concern when assessing buspirone for the treatment of addiction, which is characterized by decreases in striatal D 2 R (Volkow et al., 1990 (Volkow et al., , 1993 (Volkow et al., , 1996 (Volkow et al., , 1997 Martinez et al., 2004) . Moreover, reduced D 2 R in striatum is linked with impairment in function of the frontal cortex, which is necessary for self-control, in addicted individuals (Volkow et al., 1993 (Volkow et al., , 2001 (Volkow et al., , 2007 and in animal models, reduced signalling through D 2 R facilitates compulsive drug use (Everitt et al., 2008) . However, this should not be a concern with the use of oral buspirone. Indeed, the minimal D 2 R occupancy by oral buspirone could explain why buspirone is well tolerated in patients with Parkinson's disease (Bonifati et al., 1994) , in whom it does not produce extra-pyramidal side effects when used to treat anxiety. Furthermore, buspirone was discontinued from development as an antipsychotic drug (Sathananthan et al., 1975) , consistent with minimal effects as a D 2 R antagonist when administered orally. In this respect, buspirone may also be of value as a treatment for impulse control disorders that can occur in patients with Parkinson's disease, particularly with the use of high affinity D 3 R and D 4 R agonists (Vilas et al., 2012) . Indeed, polymorphisms in the genes encoding for D 3 R and D 4 R are implicated in the susceptibility to impulse control disorders (Lee et al., 2009; Eisenegger et al., 2010) In this study we evaluated parenteral and oral routes of administration, and used a range of doses that would be expected to cover those used therapeutically. However, dose extrapolation across routes of administration and species is potentially problematic; the i.m. doses of buspirone used (0.19 and 0.5 mg/kg) and the oral doses used (1-3 mg/kg) are likely to be at the upper range of what would be routinely administered (60 mg p.o.) for the treatment of anxiety. Nonetheless, these data indicate that therapeutic doses of busprione in humans will result in significant blockade of D 3 R (and also, by inference, D 4 R). To the extent that our findings in the non-human primate brain can be extrapolated to the human brain, our findings indicate that doses of 1.6 mg/kg (human equivalent dose for 3 mg/kg baboon dose) may be sufficient to induce >50% D 3 R occupancy. Taking into account the known fraction of [ (72%) (Rabiner et al., 2009) and minimal D 2 R blockade, D 3 R occupancy may be even higher (up to 76% in GP). Clinical studies that assess the relationship between plasma concentration of buspirone and its metabolites and the occupancy of D 3 R may help optimize dosing regimes. Oral buspirone in humans has a very wide safety margin (up to gram levels per day were administered in antipsychotic trials) (Sathananthan et al., 1975) . Therefore, higher doses of oral buspirone could be used for clinical translation of the current findings.
Our findings have implications for clinical research examining the efficacy of buspirone for the treatment of SUD. Specifically, the short lived blockade of D 3 R after oral buspirone indicates that clinical trials will require the use of significantly higher doses (at least three-fold higher) than those used currently to treat anxiety (60 mg) in order to achieve sustained high levels of D 3 R blockade. Also the difference in the pattern of receptor occupancy between oral buspirone (associated with a more selective blockade or D 3 R) and i.m. buspirone (associated with blockade of both D 2 R and D 3 R) highlight the relevance of buspirone metabolites in its pharmacological effects. Indeed, pilot data showing very high levels of D 3 R blockade after i.m. administration of 6′-hydroxybuspirone in midbrain (though not in pallidum) suggest that this metabolite warrants further investigation for its potential value in addiction treatment. The short duration of D 3 R occupancy also suggests that extended release formulations (including those of 6′-hydroxybuspirone) merit investigation for the treatment of SUD or that of other CNS conditions that target D 3 R (and/or D 4 R).
Study limitations and other considerations
The attribution of buspirone-induced changes in (Rabiner et al., 2009) , and (2) buspirone increases extracellular dopamine, which may differentially affect the binding of the two radiotracers (Gobert et al., 1999; Kaariainen et al., 2008 (Rabiner et al., 2009 ), which we attribute to both a small degree of D 2 R binding but also competition from endogenous dopamine released by buspirone (Gobert et al., 1999; Kaariainen et al., 2008) . We also cannot exclude underestimation of D 3 R occupancy due to the presence of D 3 R in CB (Ginovart et al., 2007; Rabiner et al., 2009 ), which could affect occupancy measures when using [ 11 C]PHNO (Searle et al., 2013) . In addition, unavoidable 'cold mass' in the [ 11 C]PHNO preparation (non-tracer dose) can introduce errors in the occupancy estimation (Searle et al., 2013) . Due to the slow wash-out properties of [ 11 C]PHNO, a scanning period longer than 90 min would be better for accurate quantification (Girgis et al., 2011) though this would introduce errors due to low counting statistics. Though we cannot exclude the possibility that anaesthesia may have affected radiotracer binding, we controlled the time interval between anaesthesia induction and radiotracer administration and performed all [ 11 C]PHNO studies on separate days to minimize carry-over effects from PHNO on subsequent [ 11 C]PHNO studies. Plasma analysis would have helped us elucidate the contribution of buspirone's metabolites in D 3 R occupancies and further studies would have enabled us to estimate the duration of D 3 R occupancies and to measure D 3 R occupancies after 5-hydroxybuspirone and 6′-hydroxybuspirone but the closure of the brain imaging laboratory at BNL precluded us from carrying them out. Finally, since the effects on cocaine self-administration were obtained following parenteral administration of buspirone, and we showed that i.m. buspirone occupies both D2 and D3 receptors, we cannot impute the relative importance of each receptor to the effects on cocaine self-administration
In summary, present findings demonstrate that parenteral buspirone induced a significant occupancy of D 2 R and D 3 R, whereas oral administration induced blockade mainly of D 3 R. Our results suggest that higher doses of oral buspirone than those that are typically used for the treatment of anxiety (at least three-fold higher) will be required in order to achieve and sustain the levels of D 3 R occupancies reported (Mugnaini et al., 2013) to attenuate drug craving in smokers.
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